![]() There is no evidence of patient benefit for glycoprotein inhibitors (GPI) in pretreatment. 6 Neither prasugrel nor ticagrelor have been tested in patients with stable angina. The absence of benefit from pretreatment loading is reflected in guidelines: The European Society of Cardiology (ESC) giving a IIb C recommendation for pretreatment loading only ‘if high chance of PCI’ 5 and the American Heart Association/American College of Cardiology (AHA/ACC) questioning its benefit without giving a recommendation. 3 The study finding was consolidated by a meta-analysis showing no mortality benefit from pretreatment. The only trial designed to test pretreatment was PRAGUE-8 which failed to show ischaemic benefit between prehospital 600 mg clopidogrel compared with in-laboratory treatment but with a higher risk of minor bleeding. However, closer analysis of patient inclusion revealed that most were selected after coronary angiography. The evidence for pretreatment arose from the CREDO trial 2 which demonstrated benefit if patients received clopidogrel 300 mg loading at least 6 hours before PCI. Primary endpoint: all-cause mortality, MI, stroke or ischaemia-driven target lesion revascularisationħ119 patients at HBR or high ischaemic riskĭeath from any cause, non-fatal MI, or non-fatal stroke Rivoraxaban 2.5 mg two times a day+Aspirinġ month of DAPT followed by aspirin alone Net clinical benefit: 15% reduction in Ticagrelor arm Subgroup of THEMIS patients who underwent PCI Stable CAD and type 2 diabetes, no history of previous MI/Stroke TIMI risk can be calculated on the TIMI website under "Clinical Calculators.ACS in previous 1–3 years with high ischaemia riskĪspirin+Ticagrelor 60mg two times a day vs 'TIMI risk' estimates mortality following acute coronary syndromes. 1 Pointĥ% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.Ĩ% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.ġ3% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.Ģ0% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.Ģ6% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization.Ĥ1% risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization. % risk at 14 days of: all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring urgent revascularization. *Risk factors include: family history of CAD, hypertension, hypercholesterolemia, diabetes, or being a current smoker. Severe angina (≥ 2 episodes w/in 24 hrs).Known coronary artery disease (CAD) (stenosis ≥ 50%).TIMI Score Calculation (1 point for each): In patients with UA/NSTEMI, the TIMI risk score is a prognostication scheme that categorizes a patient's risk of death and ischemic events and provides a basis for therapeutic decision making. Among the group's most important works is the TIMI Risk Score, which assesses the risk of death and ischemic events in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI). Braunwald held the chairmanship until 2010, when he appointed Marc Sabatine to the position. The TIMI Study Group was founded by physician Eugene Braunwald in 1984. The group has its headquarters in Boston, Massachusetts. The Thrombolysis In Myocardial Infarction ( TIMI) Study Group, is an academic research organization (ARO) affiliated with Brigham and Women's Hospital and Harvard Medical School with a focus in the field of cardiovascular disease. For other uses, see Timi (disambiguation). For the IBM technology, see IBM i § TIMI. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |